(Q36327987)

13 August 2017

title

The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. (English)

1 reference

13 August 2017

0 references

H F McFarland

1

1 reference

13 August 2017

S C Reingold

series ordinal

2

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Multiple Sclerosis Journal

13 August 2017

published in

1 reference

13 August 2017

volume

11

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

669-676

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

FDA uneasy about placebo revision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Fifth revision of Declaration of Helsinki: Clause 29 forbids trials from using placebos when effective treatment exists

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Methodological and statistical problems in the construction of composite measurement scales: a survey of six medical and epidemiological journals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Clinical outcomes assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Procedures for comparing samples with multiple endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

The use of subjective rankings in clinical trials with an application to cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Monitoring pairwise comparisons in multi-armed clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Competing interests in multiple sclerosis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Meta-analysis for the evaluation of potential surrogate markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

Image analysis of optic nerve disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1231OA

10.1191/1352458505MS1231OA

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference